Nicotinamide phosphoribosyltransferase (NAMPT) Peptide
NAMPT
适用: 人
宿主: 合成
WB, BP
-
- 抗原 See all NAMPT products
- NAMPT (Nicotinamide phosphoribosyltransferase (NAMPT))
- 宿主
- 人
-
资源
- 合成
- 应用范围
- Western Blotting (WB), Blocking Peptide (BP)
- 产品特性
- This is a synthetic peptide designed for use in combination with anti-PBEF1 antibody (Catalog #: ARP42254_T100). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- 纯化方法
- Purified
-
Nicotinamide phosphoribosyltransferase (NAMPT) peptide (Ovalbumin)
NAMPT 适用: 人 宿主: 合成 WB, Imm, SDS
-
- 应用备注
- Each Investigator should determine their own optimal working dilution for specific applications.
- 限制
- 仅限研究用
-
- 状态
- Lyophilized
- 溶解方式
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- 浓度
- 1 mg/mL
- 缓冲液
- Final peptide concentration is 1 mg/mL in PBS.
- 注意事项
- Avoid repeated freeze-thaw cycles.
- 储存条件
- -20 °C
- 储存方法
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- 抗原
- NAMPT (Nicotinamide phosphoribosyltransferase (NAMPT))
- 背景
-
PBEF1 catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, one step in the biosynthesis of nicotinamide adenine dinucleotide. The protein is an adipokine that is localized to the bloodstream and has various functions, including the promotion of vascular smooth muscle cell maturation and inhibition of neutrophil apoptosis. It also activates insulin receptor and has insulin-mimetic effects, lowering blood glucose and improving insulin sensitivity. The protein is highly expressed in visceral fat and serum levels of the protein correlate with obesity.
Alias Symbols: 1110035O14Rik, DKFZP666B131, MGC117256, NAMPT, PBEF, VF, PBEF1, VISFATIN
Protein Interaction Partner: FANCA
Protein Size: 491 - 分子量
- 54 kDa
- 基因ID
- 10135
- NCBI登录号
- NM_005746, NP_005737
- UniProt
- P43490
-
You are here:
